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ABSTRACT: A series of pyrido[3,4-d]azepines that are potent and selective 5-HT2C receptor agonists is disclosed. Com-
pound 7 (PF-04781340) is identified as a suitable lead owing to good 5-HT2C potency, selectivity over 5-HT2B agonism and 
in vitro ADME properties commensurate with an orally available and CNS penetrant profile. The synthesis of a novel bi-
cyclic tetra-substituted pyridine core template is outlined, including rationale to account for the unexpected formation of 
aminopyridine 13 resulting from an ammonia cascade cyclisation.  
Serotonin (5-hydroxytryptamine, 5-HT 1) acts as a neuro-
transmitter agonist of at least 14 different receptors classi-
fied into seven major families, 5-HT1-7. The 5-HT2 class of 
GPCR receptors comprises three members 5-HT2A, 5-HT2B 
and 5-HT2C. Agonism of 5-HT2C in the CNS has been rec-
ognised to have potential for the treatment of obesity, 
urinary incontinence, psychiatric disorders and sexual 
dysfunction.1 However, it has been established that selec-
tivity over agonism of structurally related receptors 5-
HT2A and 5-HT2B is required. Poorly selective agonists 
have been linked to clinical adverse events in humans. 
These include hallucinations and cardiovascular effects 
due to 5-HT2A agonism
2-3 and chronic cardiac valvulopa-
thy and pulmonary hypertension caused by 5-HT2B ago-
nism.4 Notably the anti-obesity treatment Fen-Phen was 
withdrawn in 1997 for causing irreversible valvulopathy 
which has been attributed to chronic 5-HT2B agonism. 
The resulting search for selective 5-HT2C agonists identi-
fied vabicaserin (2) (SCA-136) as a potential therapy for 
schizophrenia and lorcaserin (3) (APD-356) which was 
approved in 2012 as Belviq® for treatment of obesity (Fig-
ure 1).5 Numerous other preclinical 5-HT2C agonists have 
also been reported.6-8 
 
Figure 1. Selected 5-HT2C agonists. 
Previously Pfizer disclosed several 5-HT2C agonist series,
9-
14 including a pyrimidine-fused azepine template that led 
to the discovery of PF-03246799 (4) which offered good 
levels of in vitro and in vivo potency.14-15 However com-
pound 4, despite offering excellent selectivity over both 5-
HT2A still showed weak but measurable agonism of 5-HT2B 
at 10 M in both recombinant cell systems and native 
human tissue.14 It was later discovered that 4-
methylamino substitution 5 could offer an enhancement 
to 5-HT2C agonist potency and simultaneously offer supe-
rior selectivity over 5-HT2B.
13 However, these structural 
changes rendered amino-substituted pyrimidine com-
pound 5 a substrate for multidrug resistance P-
glycoprotein (P-gp), identified by a large efflux ratio 
(ER=10) as measured using an in vitro transfected MDCK 
cell line (Figure 2).16 A previous correlation analysis of all 
compounds tested in this MDCK-MDR1 assay concluded 
that compounds with efflux ratios of <2.5 are unlikely to 
be significantly effluxed from the CNS by P-gp whereas 
compounds with ratios >3.0 are at significant risk of ex-
hibiting appreciable CNS impairment.16 In line with this 
result, preclinical in vivo efficacy studies of compound 5 
showed prohibitive levels of CNS restriction limiting ther-
apeutic efficacy even at high plasma concentrations.16 
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Figure 2. P-gp efflux and CNS exposure. 
To retain the high 5-HT2C potency and selectivity of com-
pound 5 but with improved CNS penetration, compounds 
were sought to provide reduced P-gp efflux. Literature 
pharmacophore models for P-gp have highlighted the role 
of aromatic hydrophobic interactions and intramolecular 
hydrogen bond Acc-Acc distances of ~2.5 Å and ~4.6 Å as 
P-gp recognition features.17 As illustrated in Figure 3, 
compound 5 has Acc-Acc distances of 2.4 Å, 4.1 Å and 4.6 
Å suggesting close similarity to this P-gp pharmacophore 
pattern of hydrogen bonds.18-19 
This pointed to N-1 in compound 5 being potentially in-
strumental to P-gp recognition when combined with a 4-
amino substituent. Furthermore SAR from related tem-
plates suggested that the N-1 interaction would not be 
required for 5-HT2C activity. To test this hypothesis, sev-
eral compounds were designed to reduce the propensity 
for N-1 to interact with P-gp. This led to compounds such 
as chiral methyl azepine compound 6 that retained good 
5-HT2C potency, selectivity and reduced P-gp efflux 
(ER=2.7) that translated to improved in vivo efficacy.13, 15 It 
was further proposed that removing N-1 altogether, to 
give fused aminopyridine azepine 7, would offer good 5-
HT2C agonist potency without significant P-gp efflux lia-
bility. 
The controlled syntheses of tri- and tetra-substituted pyr-
idines, despite their favourable characteristics and popu-
larity within medicinal chemistry, present formidable 
challenges. Preferred synthetic methods typically com-
prise the selective functionalization of a pre-existing pyri-
dine ring or de novo ring synthesis. However, in this in-
stance, the need for a fused bicyclic tetra-substituted pyr-
idine meant that most known methods were not compat-
ible owing to either not supporting fused ring construc-
tion or providing the wrong substitution pattern.20 As a 
result, it was necessary to develop suitable chemistry to 
access amino-pyridine fused azepine template 7. A route 
was proposed based on limited precedent for biaryl ring 
synthesis via ammonia cyclisation of an alkyne 8 to give 
isoquinolone 9 (Scheme 1).21-22 
Scheme 1 
 
a
Reagents and conditions: (a) Tf2O, NaOtBu, CH2Cl2, 23 °C, 
0.5 h, then Tf2O, 23 °C, 2 h; (b) BnCCH, DIPEA, CuI, 
Pd(PPh3)2Cl2, DMF, 23 °C, 2 h; (c) NH3, MeOH, 80 °C, 15 h. 
Carboxybenzyl protected azepine -ketoester 10 was con-
verted to corresponding vinyl triflate 11 in 81% yield by 
treatment with triflic anhydride under basic conditions 
(Scheme 1). Sonogashira coupling with benzylacetylene 
then provided the desired yne-ene-ester 12 in preparation 
for the key cascade cyclisation to the corresponding pyri-
dinone. Treatment of 12 with excess ammonia in metha-
nol at 80 °C led to conversion of starting material to a 
single product. Rather than being the anticipated pyridi-
none, the product was instead determined to be amino-
pyridine 13. 
This unexpected result was repeated to provide gram 
quantities of aminopyridine 13 and a sample was crystal-
lized from CD3OD, enabling an X-ray structure to be ob-
tained to further confirm structure assignment (CCDC 
1024393 and supporting information).  
In order to discount a metal-mediated reaction,23 the 
ammonia cyclisation was also carried out using yne-ene-
ester 12 that had been pre-treated overnight with various 
metal scavenger resins (QPTU, QMTU, QSMP; 1g resin 
per 0.25mmol of 12). However, these pre-treatments did 
not alter yield or product distribution of the cyclisation. 
To investigate the mechanism of the cyclisation cascade 
and further establish the general applicability of this reac-
tion, several related alkyne systems were tested under the 
same reaction conditions (Table 1).  
 
Table 1. Ammonia-mediated cyclisations 
 
Cmpd Reactant 
Crude product 
ratioa 
Isolated 
yield (16) 
3 
 
(15) (16) 
12 
 
0 100 78% 
14a 
 
trace 
<5% 
0 
86% 
Rec. SM 
14b 
 
0 
trace 
<5% 
90% 
Rec. SM 
14c 
 
0 100 91% 
14d 
 
0 100 40% 
14e 
 
0 100 64% 
17e 
 
0 100 71% 
aProduct ratio determined by crude 1H NMR integration. Rec. SM dentoes 
yield of recovered starting material 
Interestingly if R1=Bn was replaced by R1=Ph 14a or R1=
nBu 
14b then the reaction did not proceed, instead returning 
mostly unreacted starting material. However, when the 
cyclisation reactant contained a benzylic R1, and aliphatic 
R2 and R3 (12, 14c-e), then cyclisation proceeded to con-
sistently give the corresponding aminopyridines 13, 16c-e 
in good yields. To rationalize these results it is proposed 
that systems where R1=Bn 14ii undergo rapid rearrange-
ment to allenes on treatment with ammonia, driven by 
extended conjugative stabilization of the allene with the 
Bn aromatic ring (Scheme 2). The allene system likely 
reacts with excess ammonia to form primary amide 18, 
either directly or via transient cyclisation of the ester car-
bonyl to form an activated electrophilic oxonium. Amide 
18 then cyclizes onto the allene via a 6-exo-dig ring clo-
sure preferentially through oxygen due to superior orbital 
overlap versus the nitrogen with the exo-allene * orbital 
to form a reactive hemi-aminal. An ammonia mediated 
ring opening to form keto-amidine 19 is then followed by 
a 6-exo-trig closure to provide the product aminopyridine 
16ii. Further support for this mechanism comes from the 
reaction of preformed primary amide 17e with ammonia 
to successfully provide aminopyridine 16e, suggesting 
amide 17e to be an intermediate on the reaction cascade. 
In contrast, aromatic alkyne-ester 14f, under identical 
reaction conditions, provided pyridinone 15f exclusively, 
with no evidence for formation of the aminopyridine 16f. 
However, if pre-formed primary amide 17f was exposed to 
the reaction conditions the anticipated pyridinone prod-
uct did not form, resulting in a mixture favouring amino-
pyridine 16f. This suggests that an alternative mechanistic 
pathway predominates for substrate 14f (Scheme 2).  
Scheme 2 
 
It is postulated that in this case the ammonia undergoes 
nucleophilic conjugate addition to the alkyne, as opposed 
to facilitating allene formation, followed by 6-exo-trig 
ring closure to directly give pyridinone 15f. However, if 
primary amide 17f is pre-formed this would necessitate 6-
endo-dig closure to give pyridinone 15f, for which orbital 
overlap is suboptimal, rationalising the observed mixture 
of pyridinone 15f and aminopyridine 16f products. Fur-
thermore, when pyridinone 15f was treated with ammonia 
under the same reaction conditions no reaction occurred, 
ruling out the formation of 16f via 15f. 
Aminopyridine 13 proved to be a versatile intermediate 
(Scheme 3). Reductive amination with aldehydes yielded 
mono-alkylated products 21a-f in moderate to good 
yields. Also, alkylation using iodomethane provided di-
methylated compound 21g. Finally, the application of 
Sandmeyer conditions enabled conversion of amino-
pyridine 13 to chloropyridine 20h. The chlorine was then 
reduced to give trisubstituted pyridine 21h (Scheme 3). 
Compounds 7 and 21a-h were investigated for their ability 
to inhibit the binding of a Cy3B™ conjugated analogue of 
serotonin to human 5-HT2C receptor utilizing fluores-
cence polarisation technology and cellular membrane 
preparations generated from recombinant Swiss 3T3 cells 
(Table 2, Ki values).
24 
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Table 2. 5-HT2C activity, physicochemistry and in vitro PK data for compounds 7 & 21a-h 
 
Cmpd R logD 
5-HT2C 5-HT2B HLM Clint 
(mL min-1 
mg-1) 
RRCK 
(×10-6 
cm/s) 
MDCK-MDR1 
AB Papp (×10
-6 
cm/s) 
MDCK-
MDR1 ER 
(BA/AB) 
EC50 
(nM)a 
Emax
a,b Ki
 (nM)a 
EC50 
(nM)a 
Emax
a,c Kb (nM)
a 
7 NHMe 0.4 9 99% 3 1484 69% - 19 8 2.5 2.8 
21a NHEt 0.6 11 79% 3 18 28% - 13 7 1.8 2.3 
21b NHCH2iPr 1.7 36 95% 12 nt nt - nt nt nt nt 
21c NHCH2cPr 1.2 21 100% 0.5 22 51% - 27 2 0.8 6.1 
21d NHnPr 1.0 nt nt 4 27 38% - 11 4 1.5 3.5 
21e NHiPr 1.0 nt nt 13 33 32% - nt 12 nt nt 
21f NHBn 1.7 158 37% 22 - - 121 35 2 0.6 3.6 
21g NMe2 0.6 nt nt 12 30 38% - 43 8 2.1 2.2 
21h H 0.5 nt nt 35 27 53% - <8 18 3.9 1.5 
aValues are geometric means of up to five experiments. Differences of <2-fold should not be considered significant; b% activation by maximum asymptote 
at 10 M relative to 5-HT; c% activation by maximum asymptote at 30 M relative to 5-HT; nt denotes not tested 
 
Scheme 3a 
 
a
Reagents and conditions: (a) aldehyde or ketone, DCE, 
AcOH, 23 °C, 30 min, then PS-BH3CN, 55 °C, 18-40 h; (b) 
Pd/C, H2, EtOH, 45 psi, 23 °C, 3-24 h; (c) MeI, K2CO3, DMF, 
80 °C, 22 h; (d) NaNO2, HCl, H2O, MeCN, 23 °C, 1 h; (e) Pd/C, 
HCOONH4, EtOH, 75 °C, 2 h.  
The 5-HT2C and 5-HT2B functional agonist activities of 
selected compounds were evaluated relative to 5-HT (1) 
by measuring ability to induce G-protein activation via 
recruitment of GTPγS and mobilization of intracellular 
calcium for 5-HT2C and 5-HT2B respectively (Table 2, EC50 
and Emax).
13, 24 Previous studies within Pfizer have shown 
compound Ki at the 5-HT2C receptor to be the most pre-
dictive indicator of free brain exposure required to elicit 
5-HT2C related pharmacological effects in vivo
25 (see SI for 
cell culture and assay protocols). 
Compounds 7 and 21a-h exhibited excellent 5-HT2C bind-
ing potency and agonist efficacy (Table 2). Varying the 2-
amino substituent sampled a range of molecular weight 
and lipophilicity. However, despite larger and more lipo-
philic substituents being generally well tolerated they 
appeared less ligand and lipophilic efficient, providing no 
appreciable improvements in 5-HT2C potency. Further-
more, although this series generally showed similar levels 
of 5-HT2B potency (EC50), the compounds were either 
weak partial agonists at 5-HT2B, characterized by low Emax 
values, or showed antagonism (compound 21f). Overall, 
compounds also tended to exhibit good metabolic stabil-
ity in human liver microsomes (HLM) and moderate to 
good passive permeability in RRCK cells.  
Methyamino-substituted pyridine compound 7 looked the 
most promising on balance of physicochemistry, potency, 
selectivity and metabolic stability. In accordance with the 
original design hypothesis, compound 7 also exhibited a 
low efflux ratio in the MDCK-MDR1 P-gp assay (P-gp 
ER=2.8), a pronounced improvement over the equivalent 
pyrimidine compound 5 (P-gp ER=10). This level of P-gp 
efflux (ER=2.8) correlates well with other examples from 
the broader azepine series such as pyrimidine compound 
6 (ER=2.7) that previously achieved good CNS exposure 
and efficacy in preclinical in vivo studies.13  
In summary, the rational design and synthesis of a series 
of pyridine-fused azepines with potent 5-HT2C agonist 
activity and low P-gp efflux ratios has been described to 
deliver lead compound 7 (PF-04781340). Chemistry was 
developed and rationalized to access this template, in-
cluding an ammonia-mediated cascade synthesis of ami-
nopyridine 13. These methods have also been extended to 
the synthesis of poly-substituted and fused bicyclic ami-
nopyridines, illustrating potential for broader application. 
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